Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right ) EBIT

The latest EBIT for BLACU is $-23M as of March 2026. That compares with $-6.4M in the prior-year period — down 255.8% year over year. That is above the sector sector average of $-69M. Investors often review this figure alongside Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BLACU's EBIT moved from $-6.4M to $-23M — a 255.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s operating scale or balance-sheet position.

Against its sector companies, BLACU currently prints $-23M for EBIT, while the sector average sits near $-69M. That is roughly 66.8% above the sector mean. Large gaps often invite a closer look at Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s growth, margins, and balance sheet.

A EBIT figure of $-23M for BLACU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting BLACU's EBIT ($-23M), review year-over-year change from $-6.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.